黑料网

ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
黑料网

Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 黑料网 Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

黑料网 Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Citations : 3314

Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • ResearchBible
  • China National Knowledge Infrastructure (CNKI)
  • Access to Global Online Research in Agriculture (AGORA)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • ICMJE
Recommended Journals
Share This Page

Analysis of the interplay between chemoresistance and pro-inflammatory effects within neuroblastoma (and other) chemoresistance cell line models

5th World Congress on Biotechnology

Duncan Ayers

Accepted Abstracts: J Biotechnol Biomater

DOI:

Abstract
The evidence for the critical clinical repercussions stemming from the simultaneous, dys-regulated expression of multiple components within both the pro-inflammatory and chemoresistance pathways is evermore present within a large spectrum of cancer conditions. The author?s team is currently investigating the level of dys-regulated gene expression of hallmark pro-inflammatory genes within multiple, validated chemoresistanttumour cell line models such as neuroblastoma, breast and prostate carcinomas.In essence, identification of these novel interplays can demonstrate to contribute key diagnostic and prognostic biomarkers that can serve the oncology clinician to take more informed clinical decisions, based on the individual tumour characteristics. Such informed clinical decisions ultimately allow for bespoke and enhanced therapeutic efficacy, possibly utilising current anti-inflammatory drug treatments, with minimal suffering to the individual cancer patient presenting with chemoresistanttumours.
Biography
Duncan Ayers has completed his PhD in Translational Medicine from The University of Manchester (UK) and is currently continuing his postdoctoral studies at The University of Malta. He is also a Research Associate with the Faculty of Medicine & Human Health Sciences at the University of Manchester. During his doctoral studies, he also spent a 17-month attachment with the Vandesompele group at the Center for Medical Genetics Ghent (Ghent University, Ghent, Belgium). He has published/presented his research in more than 34 reputed journal papers and international meetings, together with contributing to four book publications
International Conferences 2024-25
 
Meet Inspiring Speakers and Experts at our 3000+ Global

Conferences by Country

Medical & Clinical Conferences

Conferences By Subject

Top